AstraZeneca has secured the last piece to a global puzzle of licensing agreements with Ionis Pharmaceuticals for the rare heart disease drug eplontersen.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,